Frequently Asked Questions
The global oral solid dosage contract manufacturing market was valued at USD 32.5 Billion in 2022.
The oral solid dosage contract manufacturing market is expected to grow at a CAGR of 6.30% between 2023 and 2030, reaching USD 49.8 Billion in 2030.
Tablets is the leading segment by type outlook, holding over 32.7% share in terms of value in 2022.
The controlled-release segment governs the global demand for oral solid dosage contract manufacturing, holding a massive share of over 51.5% in 2022.
The medium- & small-size companies segment is expected to post the highest CAGR during the forecast period.
Asia Pacific is fueling the growth of the oral solid dosage contract manufacturing industry, with an over one-third share in 2022.
The top players include Catalent Inc; Lonza Group; Piramal Pharma Solutions; Aenova; Jubilant; Boehringer Ingelheim; AbbVie Contract Manufacturing; Patheon; Recipharm; Next Pharma AB; Siegfried AG; Corden Pharma.
The major market drivers are increasing investments by CDMOs to extend the development of oral solid dosages and the development of drug delivery technologies such as targeted drug delivery and sustained release dosage forms.
Strict regulatory approval requirements are the major market restraints.
Businesses already utilize cutting-edge technologies to increase the bioavailability of dosage forms to increase patient compliance, which are the major opportunities in the oral solid dosage contract manufacturing industry.